Relationship Between Delayed Graft Function (DGF) Severity and Predicted DGF Risk
E. Squiers,1 B. Irish,1 D. Odenheimer,1 S. Erlich,1 J. Grinyo, S. Feng, On Behalf of Quark DGF Study Investigators.
3U of Barcelona, BCN, Spain.
Meeting: 2015 American Transplant Congress
Abstract number: 448
Keywords: Cadaveric organs, Graft function, Kidney transplantation, Outcome
Results of a Large Phase 2 siRNA Study: Target Expression Translates to Therapeutic Outcomes
Results of large (N=326) P2 study showed QPI-1002, a systemically administered siRNA targeting p53, significantly reduced the clinical endpoint of severity of delayed graft function post-transplant, especially in kidneys from older donors (p<0.016); which are known to have increased p53. A P3 […]
Quark will present at The 7th GTC Ocular Disease Drug Discovery Conference. San Diego, CA. March 18-19, 2015.
A Synthetic Chemically Modified siRNA Targeting Caspase 2 as a Therapeutic Agent for Ocular Neuroprotection
A Synthetic Chemically Modified siRNA Targeting Caspase-2 as a Therapeutic Agent for Ocular europrotection
Elena Feinstein, M.D., Ph.D., CSO, Quark Pharmaceuticals
Caspase-2 is a pro-apoptotic gene specifically expressed and activated in retinal
ganglion cells following acute optic nerve injury or intraocular pressure increase.
Intravitreal administration of QPI1007 (a syntehticsiRNA targeting caspase-2)
demonstrated local RNA interference, lack of inflammatory effects and […]
Treatment with QPI-1002, a Short Interfering (SI) RNA for the
Prophylaxis of Delayed Graft Function. V. Peddi,1 L. Ratner,2 M.
Cooper,2 O. Gaber,2 S. Feng,2 P. Tso,2 V. Bowers,2 R. Naraghi,2 K. Budde,2
Polinsky,3 E. Squiers,3 S. Erlich,3 Study Investigators Group.2 1CPMC,
San Francisco, CA; 2Multiple Institutions; 3Quark Pharmaceuticals,
Introduction: Delayed graft function (DGF) can adversely affect deceased donor
renal transplant […]
Quark Pharmaceuticals to Participate in IBC’s Oligonucleotide Therapeutics: From Concept to Implementation Conference
Fremont, CA – August 3, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will participate in multiple roles at IBC’s Oligonucleotide Therapeutics: from Concept to Implementation Conference. The conference will take place August 3-5, 2009 in […]
Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
Fremont, CA – May 11, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, “PF-04523655 (REDD14NP), an siRNA Compound Targeting RTP801, Penetrates Retinal Cells Producing Target Gene Knockdown and Avoiding TLR3 Activation,” at […]
Quark Pharmaceuticals Presents at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
Fremont, CA – April 20, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will give a presentation on Tuesday, April 21 at this year’s American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting, which […]